{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:52:00Z","timestamp":1761630720319,"version":"3.41.0"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/jat\/bkv030","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:12:01Z","timestamp":1428970321000},"page":"374-386","source":"Crossref","is-referenced-by-count":22,"title":["Azole Antifungal Inhibition of Buprenorphine, Methadone and Oxycodone In Vitro Metabolism"],"prefix":"10.1093","volume":"39","author":[{"given":"David E.","family":"Moody","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang B.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,4,12]]},"reference":[{"key":"key\n\t\t\t\t20170517032435_BKV030C1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1521-0391.2009.00008.x","article-title":"Indicators of buprenorphine and methadone use and abuse: what do we know?","volume":"19","author":"Maxwell","year":"2010","journal-title":"American Journal on Addictions"},{"key":"key\n\t\t\t\t20170517032435_BKV030C2","first-page":"493","article-title":"Vital signs: risk for overdose from methadone used for pain relief\u2014United States, 1999\u20132010","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morbidity and Mortal Weekly Report"},{"key":"key\n\t\t\t\t20170517032435_BKV030C3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/17425255.2013.783567","article-title":"Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine","volume":"9","author":"Moody","year":"2013","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C4","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.2105\/AJPH.2014.301966","article-title":"Determinants of increased opioid-related mortality in the United States and Canada, 1990\u20132013: a systematic review","volume":"104","author":"King","year":"2014","journal-title":"American Journal of Public Health"},{"key":"key\n\t\t\t\t20170517032435_BKV030C5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jat\/28.7.616","article-title":"Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions","volume":"28","author":"Cone","year":"2004","journal-title":". Journal of Analytical Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"American Journal on Addictions"},{"key":"key\n\t\t\t\t20170517032435_BKV030C7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jat\/bkr013","article-title":"Blood methadone concentrations in living and deceased persons: variations over time, subject demographics, and relevance of coingested drugs","volume":"36","author":"Jones","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.18553\/jmcp.2014.20.5.467","article-title":"The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients","volume":"20","author":"Pergolizzi","year":"2014","journal-title":"Journal of Managed Care Pharmacy"},{"key":"key\n\t\t\t\t20170517032435_BKV030C9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"key\n\t\t\t\t20170517032435_BKV030C10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pharmthera.2009.10.011","article-title":"Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information","volume":"125","author":"Hisaka","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.taap.2009.12.016","article-title":"Drug interactions evaluation: an integrated part of risk assessment of therapeutics","volume":"243","author":"Zhang","year":"2010","journal-title":"Toxicology and Applied Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver micrsomes","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sciences"},{"key":"key\n\t\t\t\t20170517032435_BKV030C13","first-page":"818","article-title":"Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4","volume":"26","author":"Kobayashi","year":"1998","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","article-title":"A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies","volume":"306","author":"Moody","year":"2002","journal-title":"Analytical Biochemistry"},{"key":"key\n\t\t\t\t20170517032435_BKV030C15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","article-title":"In vitro metabolism study of buprenorphine: evidence for new metabolic pathways","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/dmd.105.006148","article-title":"Novel metabolites of buprenorphine detected in human liver microsomes and human urine","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-7843.2009.00432.x","article-title":"The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism","volume":"105","author":"Moody","year":"2009","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1017\/S1461145709990848","article-title":"Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)","volume":"13","author":"Tournier","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.112.193433","article-title":"P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception","volume":"343","author":"Brown","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00007691-199606000-00001","article-title":"Stereoselective pharmacokinetics of methadone in chronic pain patients","volume":"18","author":"Kristensen","year":"1996","journal-title":"Therapeutic Drug Monitoring"},{"key":"key\n\t\t\t\t20170517032435_BKV030C21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1213\/01.ANE.0000099723.75548.DF","article-title":"Functional inhibition by methadone of N-methyl-d-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects","volume":"98","author":"Callahan","year":"2004","journal-title":"Anesthesia and Analgesia"},{"key":"key\n\t\t\t\t20170517032435_BKV030C22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Eap","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C23","first-page":"1347","article-title":"The involvement of cytochrome P450 3A in the N-demethylation of l-a-acetylmethadol (LAAM), norLAAM and methadone","volume":"25","author":"Moody","year":"1997","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chemical Research in Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"key\n\t\t\t\t20170517032435_BKV030C27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jat\/bkt042","article-title":"Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications","volume":"37","author":"Fang","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/ecp.13.18","article-title":"A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice","volume":"6","author":"Bruce","year":"2013","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C31","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal","volume":"294","author":"Kreek","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"key\n\t\t\t\t20170517032435_BKV030C32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","article-title":"The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone","volume":"160","author":"Samer","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C34","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0b013e31819faa54","article-title":"Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone","volume":"110","author":"Nieminen","year":"2009","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C35","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejpain.2009.12.007","article-title":"St John's wort greatly reduces the concentration of oral oxycodone","volume":"14","author":"Nieminen","year":"2010","journal-title":"European Journal of Pain"},{"key":"key\n\t\t\t\t20170517032435_BKV030C36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1742-7843.2010.00582.x","article-title":"Grapefruit juice enhances the exposure to oral oxycodone","volume":"107","author":"Nieminen","year":"2010","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-010-0879-1","article-title":"Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir\/ritonavir","volume":"66","author":"Nieminen","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jat\/bkt060","article-title":"In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors","volume":"37","author":"Moody","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.113.054627","article-title":"Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges","volume":"42","author":"Johnson","year":"2014","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","article-title":"Overview of medically important antifungal azole derivatives","volume":"1","author":"Fromtling","year":"1988","journal-title":"Clinical Microbiology Reviews"},{"key":"key\n\t\t\t\t20170517032435_BKV030C41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clinic Proceedings"},{"key":"key\n\t\t\t\t20170517032435_BKV030C42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40262-014-0139-0","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications","volume":"53","author":"Stockmann","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C43","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1006\/bbrc.2001.5054","article-title":"Differential N-demethylation of l-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450 s 2B6, 2C18, and 3A4","volume":"284","author":"Neff","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"key\n\t\t\t\t20170517032435_BKV030C44","first-page":"319","article-title":"Variables in human liver microsome preparation: impact on the kinetics of l-a-acetylmethadol (LAAM) N-demethylation and dextromethorphan O-demethylation","volume":"29","author":"Nelson","year":"2001","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"Journal of Biological Chemistry"},{"key":"key\n\t\t\t\t20170517032435_BKV030C46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0024-2","article-title":"Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity","volume":"36","author":"Khojasteh","year":"2011","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jat\/32.3.208","article-title":"An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes","volume":"32","author":"Moody","year":"2008","journal-title":"Journal of Analytical Toxicology"},{"volume-title":"Guidance for Industry\u2014Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labeling (draft guidance)","year":"2006","author":"FDA, U.S.","key":"key\n\t\t\t\t20170517032435_BKV030C49"},{"key":"key\n\t\t\t\t20170517032435_BKV030C50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/dmd.111.043158","article-title":"Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions","volume":"40","author":"Mao","year":"2012","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C52","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochemical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C53","volume-title":"Physicians\u2019 Desk Reference","author":"Invanz","year":"2010","edition":"64th edition."},{"key":"key\n\t\t\t\t20170517032435_BKV030C54","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"key\n\t\t\t\t20170517032435_BKV030C55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187231209788654117","article-title":"Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases","volume":"3","author":"Chang","year":"2009","journal-title":"Drug Metabolism Letters"},{"key":"key\n\t\t\t\t20170517032435_BKV030C56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C57","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"key\n\t\t\t\t20170517032435_BKV030C58","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1248\/bpb.28.1813","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"key\n\t\t\t\t20170517032435_BKV030C59","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"key\n\t\t\t\t20170517032435_BKV030C60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.vascn.2008.05.131","article-title":"Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds","volume":"58","author":"Zientek","year":"2008","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"key\n\t\t\t\t20170517032435_BKV030C61","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2125.1991.tb03963.x","article-title":"Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes","volume":"32","author":"Back","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00314987","article-title":"In vitro forecasting of drugs which may interfere with the biotransformation of midazolam","volume":"41","author":"Gascon","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1096\/fasebj.6.2.1371482","article-title":"Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture","volume":"6","author":"Maurice","year":"1992","journal-title":"The FASEB Journal"},{"key":"key\n\t\t\t\t20170517032435_BKV030C64","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C65","first-page":"443","article-title":"Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro","volume":"4","author":"von Moltke","year":"1998","journal-title":"Pharmacy and Pharmacology Communications"},{"key":"key\n\t\t\t\t20170517032435_BKV030C66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1211\/0022357056118","article-title":"Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs","volume":"57","author":"Sakaeda","year":"2005","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C67","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1177\/0091270006293753","article-title":"Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6","volume":"46","author":"Walsky","year":"2006","journal-title":"Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2125.2000.00316.x","article-title":"The xenobiotic inhibitor profile of cytochrome P4502C8","volume":"50","author":"Ong","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1988.tb03359.x","article-title":"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinilines","volume":"26","author":"Back","year":"1988","journal-title":"British Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1081\/ERC-200035093","article-title":"Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans","volume":"30","author":"Trosken","year":"2004","journal-title":"Endocrine Research"},{"key":"key\n\t\t\t\t20170517032435_BKV030C71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0090-9556(24)15255-5","article-title":"Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C72","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.30.12.1441","article-title":"Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors","volume":"30","author":"Tran","year":"2002","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C73","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0009-9236(98)90089-3","article-title":"The effect of fluconazole on the clinical pharmacokinetics of methadone","volume":"63","author":"Cobb","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C74","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00559-06","article-title":"Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"key\n\t\t\t\t20170517032435_BKV030C77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00228-010-0893-3","article-title":"Effect of inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone","volume":"67","author":"Kummer","year":"2011","journal-title":"European Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","article-title":"Voriconazole drastically increases exposure to oral oxycodone","volume":"65","author":"Hagelberg","year":"2009","journal-title":"European Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C79","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-009-0775-8","article-title":"Effects of itraconazole on the pharmacokinetics of intravenously and orally administered oxycodone","volume":"66","author":"Saari","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"key":"key\n\t\t\t\t20170517032435_BKV030C80","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metabolism and Disposition"},{"key":"key\n\t\t\t\t20170517032435_BKV030C81","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1128\/AAC.01242-10","article-title":"Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4","volume":"55","author":"Gronlund","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"key\n\t\t\t\t20170517032435_BKV030C82","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2710.2010.01229.x","article-title":"Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model","volume":"36","author":"Miki","year":"2011","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/bmj.325.7355.77","article-title":"Interaction between warfarin and topical miconazole cream","volume":"325","author":"Devaraj","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170517032435_BKV030C84","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jaad.2005.11.1077","article-title":"Increase in anticoagulant effect of warfarin in a patient using econazole cream","volume":"55","author":"Lang","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t20170517032435_BKV030C85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/0003088-200847120-00003","article-title":"The enzymatic basis of drug-drug interactions with systemic triazole antifungals","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"key":"key\n\t\t\t\t20170517032435_BKV030C86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxlet.2011.01.027","article-title":"Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition","volume":"202","author":"Dvorak","year":"2011","journal-title":"Toxicology Letters"},{"key":"key\n\t\t\t\t20170517032435_BKV030C87","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/39\/5\/374\/17157238\/bkv030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:03:48Z","timestamp":1747919028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article-lookup\/doi\/10.1093\/jat\/bkv030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,12]]},"references-count":87,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,4,12]]},"published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkv030","relation":{},"ISSN":["1945-2403","0146-4760"],"issn-type":[{"type":"electronic","value":"1945-2403"},{"type":"print","value":"0146-4760"}],"subject":[],"published":{"date-parts":[[2015,4,12]]}}}